Comparative study of treatment of chronic plantar fasciitis using platelet rich plasma and local steroid injection

Anandkumar1, Pradeepkumar2*, Lohith N3, Mohd Mujtaba Hussain4

1Senior Resident, 2Assistant Professor, 3,4Junior Resident, 1Gulbarga Institute of Medical Sciences, Kalaburgi, Karnataka, 24Khaja Banda Nawaz Institute of Medical Sciences, Gulbarga, Karnataka, India

*Corresponding Author: Pradeepkumar
Email: drpradeepnatikar@gmail.com

Abstract
Introduction: It is one of the most common tendinopathy and most common cause of pain in the bottom of heel most cases resolve with time and conservative treatment. Local steroids injection has been one of the treatment modality from many years for patients not responding to oral medications and stretching exercises. One of recent advance in treatment of tendinopathies is use of platelet rich plasma (PRP) having the advantage of being autologous and concentrated that are rich in growth factors. In this study we have compared the efficacy of local steroid and PRP in treatment of plantar fasciitis.

Materials and Methods: Study was conducted in Kamareddy Hospital Gulbarga in the period between January 2018 and January 2019. The age of patients in our study was 20 to 50 years. In this study, 5 ml of the extracted PRP or 40 mg of triamcinolone acetate was injected into the heel area. Post-intervention, pain and functional assessment were done at 2 weeks, 6 weeks, 3 months and 6 months with Visual Analogue Score and Ankle Hind Foot scale and Foot and Ankle Disability Index score.

Results: The mean age in the steroid group was 37 and in the PRP group was 36. Right side was most commonly involved 55%. In both the groups there was significant difference in the VAS scores p<0.001 from the time of presentation to the first follow up in both the groups this further improved at the second follow up significant difference p<0.001 after which it remained constant, between the two groups there was no difference with a chi-squares p value less than 0.05 at all times.

In both the groups there was significant difference p<0.001 from the time of presentation to the first follow up in both the groups FADI score.

Interpretation & Conclusion: PRP reduces pain for longer duration as compared to steroid but the difference is not statistically significant. Disadvantages with PRP are cost and cumbersome procedure to make it. Most Patients preffered steroid over PRP due to cost.

Keywords: Platelet rich plasma (PRP), Foot and ankle disability index (FADI).

Introduction
Plantar fascitis is commonest cause of foot pain in the world. It is common in the age group of 40-50 years. It is a degenerative condition that occurs near the site of origin of the plantar fascia at the medial tuberosity of the calcaneous. Histological findings suggest that it is a chronic degenerative process, not an acute inflammatory one.

Conservative treatment for plantar fasciitis in the form of stretching, nonsteroidal anti-inflammatory medicines, night splinting, strapping, orthoses, and shoe modifications are effective for 90% of cases. Ten percent remain resistant to these treatments necessitating more aggressive intervention including injection therapy, extra corporeal shock wave therapy (ESWT), and in some instances surgical release of the origin of the plantar fascia.

Steroid injections are a popular method of treating the condition. However, the lack of an inflammatory process histologically in plantar fasciitis questions its mode of action.

Recently, promising results were reported with the use of platelet-rich plasma (PRP) injections for treating muscle and tendon injuries and degeneration. PRP is a bioactive component of whole blood with platelet concentrations elevated above baseline and containing high levels of various growth factors. The rationale for PRP benefit lies in reversing the blood ratio by decreasing red blood cells (RBC) to 5%, which are less useful in the healing process, and increasing platelets to 94% to stimulate recovery. An increased awareness of platelets and their role in the healing process has led to the concept of therapeutic applications. There is a emerging literature on the beneficial effects of PRP for chronic non-healing tendon injuries including lateral epicondylitis and plantar fasciitis.

PRP increases tendon regenerative abilities with a high content of cytokines and cells, in hyper physiologic doses, which should promote cellular chemotaxis, matrix synthesis, and proliferation. Degranulation of the alpha granules in platelets releases many different growth factors that can play a role in tissue regeneration processes. PRP represents a treatment option for many foot and ankle pathologies, including tendinopathy (Achilles, peroneal, posterior tibial, flexor hallucis longus, anterior tibial) and chronic ligamentous injury, such as plantar fasciitis.

Aim of Study
To assess the efficacy of PRP and local corticosteroid injection for treating chronic plantar fasciitis and provide initial clinical assessment of its effectiveness.
**Materials and Methods**

The randomised control study involving 50 patients was conducted in Kamareddy orthopaedic and trauma hospital, Gulbarga, Karnataka in the period between January 2018 and January 2019.

**Inclusion criteria**
1. Patients aged between 20-50 years who failed to respond to conservative management.
2. Patients who are willing to participate in the study.

**Exclusion criteria**
1. Patients of plantar fasciitis in presence of other systemic disease like diabetes mellitus, rheumatoid arthritis, and gout.
2. Hemoglobin < 5.0.
3. Any wound or skin lesion at the plantar aspect of the foot.
4. Pregnancy
5. Severe infection, known malignancy, bleeding disorder, previous surgery.
6. Nerve-related symptoms such as radiculopathy, tarsal tunnel syndrome or tarsal sinus syndrome; foot and ankle osteoarthritis.

**Methodology**

All eligible patients satisfying the inclusion criteria will be enrolled and informed written consent will be taken and the patients will be allocated into one of the two groups by computer generated algorithm for the purpose of randomization of sample and one group will receive PRP concentrate and other group will receive corticosteroid injection.

In this study,
1. 3 ml of the extracted PRP is injected into the affected area.
2. 40 mg of prednisolone (2ml) is injected into the affected area.

Post intervention both the groups will be evaluated for Post-intervention pain and functional assessment at 2 weeks, 6 weeks, 3 months and 6 months. Baseline Visual Analogue Score (VAS), Ankle Hind Foot scale and Foot and Ankle Disability Index (FADI) score is recorded.

**Results**

The study is a comparative case control randomized observational prospective study conducted in Kamareddy ortho and trauma care hospital Gulbarga in the period between January 2018 and January 2019 in patients with chronic plantar fasciitis who have satisfied the inclusion criteria and exclusion criteria.

In our study we had a total of 50 cases, 25 in the steroid group and 25 in the PRP group.

The least age in our study is 20 years and the maximum age is 50 years, the mean age in the steroid group is 37 and in the PRP group is 36 years.

In the present study overall males appeared to be more affected with plantar fasciitis in both the groups there is statistically significant difference, hence the two groups were comparable.

In the steroid group 5 were bilateral, 7 were left and 13 were right side respectively and in the PRP group 2 bilateral, 10 were left and 13 were right side respectively. Right side is most commonly involved.

The most common occupation involved was (farmers 30%) followed by (shop keepers 25%) and then (teachers 15%).

In the steroid group 35% and in the PRP group 40% were overweight, overall 56%.

**Table 1: VAS - at various interval**

|        | VAS -At presentation | VAS - 1st follow up | VAS - 2nd follow up | VAS - 3rd follow up | VAS - 4th follow up |
|--------|----------------------|---------------------|---------------------|---------------------|---------------------|
| PRP    | 7.2                  | 4.7                 | 3.7                 | 5.5                 | 4.57                |
| STEROID | 7.06                | 4.23                | 3.62                | 4.53                | 4.05                |
| p value | 0.085                | 0.048               | 0.051               | 0.06                | 0.067               |

In both the groups there is significant difference in the VAS scores p<0.001 from the time of presentation to the first follow up in both the groups this further improved at the second follow up significant difference p<0.001 after which it remained a constant, between the two groups. There is no difference with a chi-squares p value is less than 0.05 at all times.

**Table 2: FADI - at various intervals**

|        | FADI -At presentation | FADI -1st follow up | FADI -3rd follow up | FADI - 4th follow up |
|--------|-----------------------|---------------------|---------------------|---------------------|
| PRP    | 36.33                 | 76.33               | 80                  | 71.2                |
| Steroid | 36.8                 | 79.38               | 84.68               | 79.39               |
| p value | 0.901                | 0.082               | 0.0751              | 0.052               |

In both the groups there is significant difference p<0.001 from the time of presentation to the first follow up in both the groups FADI score.
Discussion
Tendinopathy refers to a condition that occurs within a tendon as a result of repeated trauma and overuse. The condition is painful and most often affects the quality of life in the working population. Among all the known tendinopathies, plantar fasciitis and tennis elbow account for most cases.19

In the present day, corticosteroid injections are considered as the treatment of choice for tendinopathies, but they are known for complications like tendon damage and can even cause tendons to rupture. One of the emerging therapeutic modalities is the use of platelet-rich plasma for tendinopathies having the advantage of being autologous and concentrated that are rich in growth factor proteins that promote the healing process.

Comparison of VAS scores
A study by Gyneshwar Tank et al.20 within group comparison in PRP group the results are statistically significant (p < 0.05). The mean VAS score decreased from baseline continuously at 4, 8, 12, and up to 24 weeks. The VAS score is statistically significant in comparison with baseline at all durations. We have seen that within group comparison for steroid group, the results are also statistically significant. The mean VAS score decreased from baseline continuously at 4, 8, and up to 12 weeks. But at the end of 24 weeks, there is rise in VAS score when compared to score at 12 weeks.

Ming-Yen Hsiao21 autologous blood-derived products followed by CSs, were best in providing relief from pain at 3 months. SW therapy and ABPs had similar probabilities of providing pain relief at 6 months, and were better than CSs at that time which is similar to our study.

Babak Vahdatpour,22 Creaney et al.23 also demonstrated statistically significant improvement in the pain scores with PRP similar to our study.

Conclusion
PRP has a better effect on pain in patients with longer duration as compared to local steroids but the difference is not statistically significant. We prefer PRP over steroid for treatment of chronic plantar fasciitis due to better effect on pain with longer duration and side effects of steroids.

Source of funding
None.

Conflict of interest
None.

References
1. Buchbinder R. Clinical practice. Plantar fasciitis. N Engl J Med 2004;350:2159-66.
2. Lemont H, Ammirati KM, Usen N. Plantar fasciitis: a degenerative process (Fasciitis) without inflammation. J Am Podiatr Med Assoc 2003;93(3):234-7.
3. Mark W. Scioli, MD. Platelet-rich Plasma Injection for Proximal Plantar Fasciitis. Tech Foot & Ankle 2011;10:7-10.
4. Kalaci A, Cakici H, Hapa O. Treatment of plantar fasciitis using four different local injection modalities: a randomized, prospective clinical trial. J Am Podiatr Med Assoc 2009;99(2):108–13.
5. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: Implications for wound healing. Plast Reconstr Surg 2004;114:1502-8
6. Filardo G, Kon E, Della Villa S, Vincintelli F, Fornasari PM, Maracci M. Use of platelet-rich plasma for the treatment of refractory jumper’s knee. Int Orthop 2010;34:909–915
7. Foster TE, Pusks BL, Mandelbaum BR. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med 2009;37:2259-72.
8. Gollwitzer H, Diehl P, von Korff A. Extracorporeal shock wave therapy for chronic painful heel syndrome: a prospective, double-blind, randomized trial assessing the efficacy of a new electromagnetic shock wave device. J Foot Ankle Surg 2007;46:348–57.
9. Gosens T, Den Oudsten BL, Fieve E, van’t Spijker P, Fievez A. Pain and activity levels before and after platelet-rich plasma injection treatment of patellar tendinopathy; a prospective cohort study and the influence of previous treatments. Int Orthop 2012;36:1941–6.
10. Hall MP, Band PA, Meislin RJ. Platelet-rich plasma: current concepts and application in sports medicine. J Am Acad Orthop Surg 17:602–8.
11. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med 2006;34:1774–8.
12. Ferrari M, Zia S, Valbonesi M. A new technique for hemodilution, preparation of autologous platelet intraoperative blood salvage in cardiac surgery. Int J Artif Organs 1987;10:47–50.
13. Hall MP, Brand PA, Meislin RJ. Platelet-rich plasma: Current concepts and application in sports medicine. J Am Acad Orthop Surg 2009;17:602-9.
14. Marx R, Garg A. Dental and craniofacial applications of platelet-rich plasma. Carol Stream: Quintessence Publishing Co, Inc; 2005.
15. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med 2006;10(10): 1–5.
16. Barrett S, Erredge S. Growth factors for chronic plantar fasciitis. Podiatry Today 2004;17:37–42
17. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004;62:489-96.
18. Martinelli N, Marinozzi A, Carni S, Trovato U, Bianchi A, Denaro V. Platelet-rich plasma injections for chronic plantar fasciitis.
19. Orchard J. Plantar fasciitis. BMJ 2012;345:e6603.
20. Tank G, Gupta R, Gupta G, Rohila R. Comparative Study of Platelet-rich Plasma and Corticosteroid Injection in the Treatment of Plantar Fasciitis. J Foot Ankle Surg (Asia-Pacific) 2017;4(2):84:9.
21. Lee TG, Ahmad TS. Intraleansional autologous blood injection compared to corticosteroid injection for treatment of chronic plantar fasciitis. A prospective, randomized, controlled trial. Foot Ankle Int 2007;28(9):984-90.
22. Hsiao MY, Hung CY, Chang KV, Chien KL, Tu YK, Wang TG. Comparative effectiveness of autologous blood-derived products, shock-wave therapy and corticosteroids for treatment of plantar fasciitis: a network meta-analysis. Rheumatol 2015;54(9):1735-43.
23. Vahdatpour B, Kianimehr L, Ahrar MH. Autologous platelet-rich plasma compared with whole blood for the treatment of chronic plantar fasciitis; a comparative clinical trial. Adv Biomed Res 2016;5.
24. Raeissadat SA, Sedighipour L, Rayegani SM, Bahrami MH, Bayat M, Rahimi R. Effect of platelet-rich plasma (PRP) versus autologous whole blood on pain and function improvement in tennis elbow: A randomized clinical trial. Pain Res Treat 2014;2014:191525.

**How to cite this article:** Anandkumar, Pradeepkumar, Lohith N, Hussain MM. Comparative study of treatment of chronic plantar fasciitis using platelet rich plasma and local steroid injection. *Indian J Orthop Surg* 2019;5(3):196-9.